Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.

Suzuki H, Gen K, Inoue Y, Hibino H, Mikami A, Matsumoto H, Mikami K.

Int J Psychiatry Clin Pract. 2014 Jan;18(1):58-62. doi: 10.3109/13651501.2013.845218. Epub 2013 Nov 13.

PMID:
24047427
2.

Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia.

Suzuki H, Gen K, Otomo M, Inoue Y, Hibino H, Mikami A, Matsumoto H, Mikami K.

Hum Psychopharmacol. 2014 May;29(3):244-50. doi: 10.1002/hup.2393. Epub 2014 Feb 17.

PMID:
24911575
3.

Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia.

Suzuki H, Gen K, Otomo M, Inoue Y, Hibino H, Mikami A, Matsumoto H, Mikami K.

Psychiatry Clin Neurosci. 2013 Feb;67(2):76-82. doi: 10.1111/pcn.12026.

4.

Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents.

Kim EY, Chang SM, Shim JC, Joo EJ, Kim JJ, Kim YS, Ahn YM.

Curr Med Res Opin. 2013 Oct;29(10):1231-40. doi: 10.1185/03007995.2013.816277. Epub 2013 Jul 16.

PMID:
23777311
5.

Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.

Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, Kim JM, Shin IS, Yoon JS.

Int Clin Psychopharmacol. 2012 Sep;27(5):267-74. doi: 10.1097/YIC.0b013e328356acad.

PMID:
22809972
6.

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.

Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM.

BMC Psychiatry. 2011 Feb 7;11:21. doi: 10.1186/1471-244X-11-21.

7.

Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.

Zalsman G, Carmon E, Martin A, Bensason D, Weizman A, Tyano S.

J Child Adolesc Psychopharmacol. 2003 Fall;13(3):319-27.

PMID:
14642020
8.

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.

Gattaz WF, Campos JA, Lacerda AL, Henna E, Ruschel SI, Bressan RA, de Oliveira IR, Rocha FL, Grabowski HM, Sacomani E Jr, Louzã MR, Quevedo J, Elkis H, Zorzetto Filho D, Périco Cde A, Lawson FL, Appolinário JC.

Curr Med Res Opin. 2014 Apr;30(4):695-709. doi: 10.1185/03007995.2013.869201. Epub 2013 Dec 16.

PMID:
24289141
9.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731
10.

A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.

Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M.

Int J Geriatr Psychiatry. 2000 Jun;15(6):506-14.

PMID:
10861916
11.

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Li H, Rui Q, Ning X, Xu H, Gu N.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8. doi: 10.1016/j.pnpbp.2011.02.001. Epub 2011 Feb 18.

PMID:
21315787
12.

The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.

Kim SW, Yoon JS, Kim YS, Ahn YM, Kim CE, Go HJ, Chee IS, Jung SW, Chung YC, Kim YD, Joe S, Lee J, Kwon YJ, Yoon BH, Jae YM.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):228-35. doi: 10.1016/j.pnpbp.2012.04.004. Epub 2012 Apr 10.

PMID:
22516251
13.
14.

Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.

Rainer MK, Masching AJ, Ertl MG, Kraxberger E, Haushofer M.

J Clin Psychiatry. 2001 Nov;62(11):894-900.

PMID:
11775050
15.

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.

Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M.

Acta Psychiatr Scand. 1997 Jan;95(1):40-3.

PMID:
9051159
16.

Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.

Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, Yoon JS.

Hum Psychopharmacol. 2009 Oct;24(7):565-73. doi: 10.1002/hup.1057.

PMID:
19790174
17.

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA.

J Clin Psychiatry. 2006 Jul;67(7):1093-103.

PMID:
16889453
18.
19.

Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.

Kozarić-Kovacić D, Pivac N, Mück-Seler D, Rothbaum BO.

J Clin Psychiatry. 2005 Jul;66(7):922-7.

PMID:
16013909
20.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738

Supplemental Content

Support Center